GARDASIL: prophylactic human papillomavirus vaccine development--from bench top to bed-side

Area of Science:

• Immunology
• Vaccinology
• Oncology

Background:

• Human papillomavirus (HPV) is a common virus linked to various cancers.
• Cervical cancer and genital warts represent significant public health concerns.
• Existing preventative measures for HPV infections were limited prior to vaccine development.

Purpose of the Study:

• To describe the preclinical and pharmaceutical development of GARDASIL.
• To present in vivo animal evaluation data for the vaccine.
• To summarize clinical trial findings for GARDASIL in women aged 9-26 years.

Main Methods:

• Development of a quadrivalent vaccine using recombinant virus-like particles (VLPs) from HPV types 6, 11, 16, and 18.
• Preclinical studies including in vivo animal model evaluations.
• Conducting clinical trials to assess safety and efficacy in the target population.

Main Results:

• GARDASIL is a non-infectious, highly purified recombinant vaccine.
• Preclinical and animal studies demonstrated vaccine potential.
• Clinical trials confirmed the vaccine's efficacy in preventing HPV-related precancerous lesions and diseases.

Conclusions:

• GARDASIL is the first vaccine approved for preventing cervical cancer, genital warts, and precancerous lesions caused by HPV types 6, 11, 16, and 18.
• The vaccine represents a significant advancement in HPV prevention for women aged 9-26.
• The comprehensive development process supports GARDASIL's role in public health.